State-of-the-art CMR Mapping Techniques in the Detection of Subclinical Chemotherapy-induced Cardiotoxicity in Breast Cancer Patients

Noura Abdelmonem Atia; Lorenz Lehmann; Mohamed Adel Eltomey; Mohamed Alm El-Din; Johannes Riffel; Constantin Dreher; Philipp Bäumer; Anoshirwan Andrej Tavakoli; Norbert Frey; Heinz-Peter Schlemmer; Matthias Friedrich; Mahmoud Abdelaziz Dawoud

doi:doi:10.11648/j.ijmi.20210901.13

State-of-the-art CMR Mapping Techniques in the Detection of Subclinical Chemotherapy-induced Cardiotoxicity in Breast Cancer Patients

Noura Abdelmonem Atia, Lorenz Lehmann, Mohamed Adel Eltomey, Mohamed Alm El-Din, Johannes Riffel, Constantin Dreher, Philipp Bäumer, Anoshirwan Andrej Tavakoli, Norbert Frey, Heinz-Peter Schlemmer, Matthias Friedrich, Mahmoud Abdelaziz Dawoud

Published in International Journal of Medical Imaging (Volume 9, Issue 1)

Received: 23 December 2020 Accepted: 30 December 2020 Published: 15 January 2021

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Background: The oncological treatments have improved survival rates but with an increased risk of cardiovascular disease (CVD). Purpose: To detect subclinical cardiotoxic changes using Cardiovascular Magnetic Resonance (CMR) and to define parameters for the prediction of late cardiac changes after 3 months follow-up. Patients and methods: We conducted a prospective study in 21 breast cancer patients who were scheduled to undergo treatment either with anthracyclines, trastuzumab, or docetaxel. CMR scans were performed before therapy onset as well as 3-6 days and 3 months thereafter. Native left ventricular (LV) T1 and T2 parameters were acquired in addition to standard parameters. Results: Compared to baseline, the mean left ventricular ejection fraction (LVEF) tended to mildly decrease during follow-up. A significant reduction in mean native T1 was found from 1246.6 ± 29.5 ms at baseline to 1231.4 ± 31.4 ms at 3-6 days, which was followed by significant increase after 3 months reaching 1265.8 ± 27.9 ms with p = 0.011 and 0.012, respectively. A significant increase in mean T2 was also found from 41.6 ± 3.4 ms at baseline to 43.8 ± 3.8 ms after 3 months with p = 0.045. From 21 patients, only 1 patient (4.8%) experienced cardiotoxicity. Conclusion: Treatment with potentially cardiotoxic drugs is associated with a change of CMR-derived native T1 which may enable an early identification of cardiotoxicity among breast cancer patients.

Published in	International Journal of Medical Imaging (Volume 9, Issue 1)
DOI	10.11648/j.ijmi.20210901.13
Page(s)	29-35
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

Breast Cancer, Anthracyclines, Trastuzumab, Cardiotoxicity, T1 Mapping, Cardiac MRI

References

[1]	Ferreira de Souza T, Quinaglia T, Neilan TG, Coelho-Filho OR (2019) Assessment of Cardiotoxicity of Cancer Chemotherapy: The Value of Cardiac MR Imaging. Magn Reson Imaging Clin N Am 27 (3): 533-544. doi: 10.1016/j.mric.2019.04.001.
[2]	Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M (2014) Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc 89 (9): 1287-1306. doi: 10.1016/j.mayocp.2014.05.013.
[3]	Adao R, de Keulenaer G, Leite-Moreira A, Bras-Silva C (2013) Cardiotoxicity associated with cancer therapy: pathophysiology and prevention strategies. Rev Port Cardiol 32 (5): 395-409. doi: 10.1016/j.repc.2012.11.002.
[4]	Jordan JH, Vasu S, Morgan TM, D'Agostino RB, Jr., Melendez GC, Hamilton CA, Arai AE, Liu S, Liu CY, Lima JA, Bluemke DA, Burke GL, Hundley WG (2016) Anthracycline-Associated T1 Mapping Characteristics Are Elevated Independent of the Presence of Cardiovascular Comorbidities in Cancer Survivors. Circ Cardiovasc Imaging 9 (8). doi: 10.1161/CIRCIMAGING.115.004325.
[5]	Chen-Scarabelli C, McRee C, Leesar MA, Hage FG, Scarabelli TM (2017) Comprehensive review on cardio-oncology: Role of multimodality imaging. J Nucl Cardiol 24 (3): 906-935. doi: 10.1007/s12350-016-0535-y.
[6]	Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, Tian G, Kirkpatrick ID, Singal PK, Krahn M, Grenier D, Jassal DS (2011) The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 57 (22): 2263-2270. doi: 10.1016/j.jacc.2010.11.063.
[7]	Shimoyama M, Murata Y, Sumi K-I, Hamazoe R, Komuro I (2001) Docetaxel induced cardiotoxicity. Heart 86 (2): 219. doi: 10.1136/heart.86.2.219.
[8]	Ong G, Brezden-Masley C, Dhir V, Deva DP, Chan KKW, Chow CM, Thavendiranathan D, Haq R, Barfett JJ, Petrella TM, Connelly KA, Yan AT (2018) Myocardial strain imaging by cardiac magnetic resonance for detection of subclinical myocardial dysfunction in breast cancer patients receiving trastuzumab and chemotherapy. Int J Cardiol 261: 228-233. doi: 10.1016/j.ijcard.2018.03.041.
[9]	Muehlberg F, Funk S, Zange L, von Knobelsdorff-Brenkenhoff F, Blaszczyk E, Schulz A, Ghani S, Reichardt A, Reichardt P, Schulz-Menger J (2018) Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathy. ESC Heart Fail 5 (4): 620-629. doi: 10.1002/ehf2.12277.
[10]	Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D (2002) Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience. Journal of Clinical Oncology 20 (5): 1215-1221. doi: 10.1200/JCO.2002.20.5.1215.
[11]	Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, Lamantia G, Colombo N, Cortinovis S, Dessanai MA, Nolè F, Veglia F, Cipolla CM (2010) Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28 (25): 3910-3916. doi: 10.1200/jco.2009.27.3615.
[12]	Drafts BC, Twomley KM, D'Agostino R, Jr., Lawrence J, Avis N, Ellis LR, Thohan V, Jordan J, Melin SA, Torti FM, Little WC, Hamilton CA, Hundley WG (2013) Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging 6 (8): 877-885. doi: 10.1016/j.jcmg.2012.11.017.
[13]	Yu AF, Chan AT, Steingart RM (2019) Cardiac Magnetic Resonance and Cardio-Oncology: Does T2 Signal the End of Anthracycline Cardiotoxicity? J Am Coll Cardiol 73 (7): 792-794. doi: 10.1016/j.jacc.2018.11.045.
[14]	Meyersohn NM, Pursnani A, Neilan TG (2015) Detection of Cardiac Toxicity Due to Cancer Treatment: Role of Cardiac MRI. Curr Treat Options Cardiovasc Med 17 (8): 396. doi: 10.1007/s11936-015-0396-8.
[15]	Nakano S, Takahashi M, Kimura F, Senoo T, Saeki T, Ueda S, Tanno J, Senbonmatsu T, Kasai T, Nishimura S (2016) Cardiac magnetic resonance imaging-based myocardial strain study for evaluation of cardiotoxicity in breast cancer patients treated with trastuzumab: A pilot study to evaluate the feasibility of the method. Cardiol J 23 (3): 270-280. doi: 10.5603/CJ.a2016.0023.
[16]	Haslbauer JD, Lindner S, Valbuena-Lopez S, Zainal H, Zhou H, D'Angelo T, Pathan F, Arendt CA, Bug G, Serve H, Vogl TJ, Zeiher AM, Carr-White G, Nagel E, Puntmann VO (2019) CMR imaging biosignature of cardiac involvement due to cancer-related treatment by T1 and T2 mapping. Int J Cardiol 275: 179-186. doi: 10.1016/j.ijcard.2018.10.023.
[17]	Galan-Arriola C, Lobo M, Vilchez-Tschischke JP, Lopez GJ, de Molina-Iracheta A, Perez-Martinez C, Aguero J, Fernandez-Jimenez R, Martin-Garcia A, Oliver E, Villena-Gutierrez R, Pizarro G, Sanchez PL, Fuster V, Sanchez-Gonzalez J, Ibanez B (2019) Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity. J Am Coll Cardiol 73 (7): 779-791. doi: 10.1016/j.jacc.2018.11.046.
[18]	Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P, Mascherbauer J, Nezafat R, Salerno M, Schelbert EB, Taylor AJ, Thompson R, Ugander M, van Heeswijk RB, Friedrich MG (2017) Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson 19 (1): 75. doi: 10.1186/s12968-017-0389-8.
[19]	Loffler AI, Salerno M (2018) Cardiac MRI for the evaluation of oncologic cardiotoxicity. J Nucl Cardiol 25 (6): 2148-2158. doi: 10.1007/s12350-018-1293-9.
[20]	Gammella E, Maccarinelli F, Buratti P, Recalcati S, Cairo G (2014) The role of iron in anthracycline cardiotoxicity. Front Pharmacol 5: 25. doi: 10.3389/fphar.2014.00025.

Cite This Article

Plain Text BibTeX RIS

APA Style

Noura Abdelmonem Atia, Lorenz Lehmann, Mohamed Adel Eltomey, Mohamed Alm El-Din, Johannes Riffel, et al. (2021). State-of-the-art CMR Mapping Techniques in the Detection of Subclinical Chemotherapy-induced Cardiotoxicity in Breast Cancer Patients. International Journal of Medical Imaging, 9(1), 29-35. https://doi.org/10.11648/j.ijmi.20210901.13

Copy | Download

ACS Style

Noura Abdelmonem Atia; Lorenz Lehmann; Mohamed Adel Eltomey; Mohamed Alm El-Din; Johannes Riffel, et al. State-of-the-art CMR Mapping Techniques in the Detection of Subclinical Chemotherapy-induced Cardiotoxicity in Breast Cancer Patients. Int. J. Med. Imaging 2021, 9(1), 29-35. doi: 10.11648/j.ijmi.20210901.13

Copy | Download

AMA Style

Noura Abdelmonem Atia, Lorenz Lehmann, Mohamed Adel Eltomey, Mohamed Alm El-Din, Johannes Riffel, et al. State-of-the-art CMR Mapping Techniques in the Detection of Subclinical Chemotherapy-induced Cardiotoxicity in Breast Cancer Patients. Int J Med Imaging. 2021;9(1):29-35. doi: 10.11648/j.ijmi.20210901.13

Copy | Download

@article{10.11648/j.ijmi.20210901.13,
  author = {Noura Abdelmonem Atia and Lorenz Lehmann and Mohamed Adel Eltomey and Mohamed Alm El-Din and Johannes Riffel and Constantin Dreher and Philipp Bäumer and Anoshirwan Andrej Tavakoli and Norbert Frey and Heinz-Peter Schlemmer and Matthias Friedrich and Mahmoud Abdelaziz Dawoud},
  title = {State-of-the-art CMR Mapping Techniques in the Detection of Subclinical Chemotherapy-induced Cardiotoxicity in Breast Cancer Patients},
  journal = {International Journal of Medical Imaging},
  volume = {9},
  number = {1},
  pages = {29-35},
  doi = {10.11648/j.ijmi.20210901.13},
  url = {https://doi.org/10.11648/j.ijmi.20210901.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijmi.20210901.13},
  abstract = {Background: The oncological treatments have improved survival rates but with an increased risk of cardiovascular disease (CVD). Purpose: To detect subclinical cardiotoxic changes using Cardiovascular Magnetic Resonance (CMR) and to define parameters for the prediction of late cardiac changes after 3 months follow-up. Patients and methods: We conducted a prospective study in 21 breast cancer patients who were scheduled to undergo treatment either with anthracyclines, trastuzumab, or docetaxel. CMR scans were performed before therapy onset as well as 3-6 days and 3 months thereafter. Native left ventricular (LV) T1 and T2 parameters were acquired in addition to standard parameters. Results: Compared to baseline, the mean left ventricular ejection fraction (LVEF) tended to mildly decrease during follow-up. A significant reduction in mean native T1 was found from 1246.6 ± 29.5 ms at baseline to 1231.4 ± 31.4 ms at 3-6 days, which was followed by significant increase after 3 months reaching 1265.8 ± 27.9 ms with p = 0.011 and 0.012, respectively. A significant increase in mean T2 was also found from 41.6 ± 3.4 ms at baseline to 43.8 ± 3.8 ms after 3 months with p = 0.045. From 21 patients, only 1 patient (4.8%) experienced cardiotoxicity. Conclusion: Treatment with potentially cardiotoxic drugs is associated with a change of CMR-derived native T1 which may enable an early identification of cardiotoxicity among breast cancer patients.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - State-of-the-art CMR Mapping Techniques in the Detection of Subclinical Chemotherapy-induced Cardiotoxicity in Breast Cancer Patients
AU  - Noura Abdelmonem Atia
AU  - Lorenz Lehmann
AU  - Mohamed Adel Eltomey
AU  - Mohamed Alm El-Din
AU  - Johannes Riffel
AU  - Constantin Dreher
AU  - Philipp Bäumer
AU  - Anoshirwan Andrej Tavakoli
AU  - Norbert Frey
AU  - Heinz-Peter Schlemmer
AU  - Matthias Friedrich
AU  - Mahmoud Abdelaziz Dawoud
Y1  - 2021/01/15
PY  - 2021
N1  - https://doi.org/10.11648/j.ijmi.20210901.13
DO  - 10.11648/j.ijmi.20210901.13
T2  - International Journal of Medical Imaging
JF  - International Journal of Medical Imaging
JO  - International Journal of Medical Imaging
SP  - 29
EP  - 35
PB  - Science Publishing Group
SN  - 2330-832X
UR  - https://doi.org/10.11648/j.ijmi.20210901.13
AB  - Background: The oncological treatments have improved survival rates but with an increased risk of cardiovascular disease (CVD). Purpose: To detect subclinical cardiotoxic changes using Cardiovascular Magnetic Resonance (CMR) and to define parameters for the prediction of late cardiac changes after 3 months follow-up. Patients and methods: We conducted a prospective study in 21 breast cancer patients who were scheduled to undergo treatment either with anthracyclines, trastuzumab, or docetaxel. CMR scans were performed before therapy onset as well as 3-6 days and 3 months thereafter. Native left ventricular (LV) T1 and T2 parameters were acquired in addition to standard parameters. Results: Compared to baseline, the mean left ventricular ejection fraction (LVEF) tended to mildly decrease during follow-up. A significant reduction in mean native T1 was found from 1246.6 ± 29.5 ms at baseline to 1231.4 ± 31.4 ms at 3-6 days, which was followed by significant increase after 3 months reaching 1265.8 ± 27.9 ms with p = 0.011 and 0.012, respectively. A significant increase in mean T2 was also found from 41.6 ± 3.4 ms at baseline to 43.8 ± 3.8 ms after 3 months with p = 0.045. From 21 patients, only 1 patient (4.8%) experienced cardiotoxicity. Conclusion: Treatment with potentially cardiotoxic drugs is associated with a change of CMR-derived native T1 which may enable an early identification of cardiotoxicity among breast cancer patients.
VL  - 9
IS  - 1
ER  -

Copy | Download

Author Information

Noura Abdelmonem Atia

Department of Diagnostic Radiology, Faculty of Medicine, Tanta University, Tanta, Egypt
Lorenz Lehmann

DepaDZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg/Mannheim, Heidelberg, Germanyrtment of Cardiology, Heidelberg University Hospital, Heidelberg, Germany
Mohamed Adel Eltomey

Department of Diagnostic Radiology, Faculty of Medicine, Tanta University, Tanta, Egypt
Mohamed Alm El-Din

Department of Clinical Oncology, Faculty of Medicine, Tanta University, Tanta, Egypt
Johannes Riffel

Department of Cardiology, Heidelberg University Hospital, Heidelberg, Germany
Constantin Dreher

Department of Radiation Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
Philipp Bäumer
Anoshirwan Andrej Tavakoli

DKFZ (German Cancer Research Center), Department of Radiology, Heidelberg, Germany
Norbert Frey

Department of Cardiology, Heidelberg University Hospital, Heidelberg, Germany
Heinz-Peter Schlemmer

DKFZ (German Cancer Research Center), Department of Radiology, Heidelberg, Germany
Matthias Friedrich

Department of Cardiology, Heidelberg University Hospital, Heidelberg, Germany
Mahmoud Abdelaziz Dawoud

Department of Diagnostic Radiology, Faculty of Medicine, Tanta University, Tanta, Egypt

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Noura Abdelmonem Atia, Lorenz Lehmann, Mohamed Adel Eltomey, Mohamed Alm El-Din, Johannes Riffel, et al. (2021). State-of-the-art CMR Mapping Techniques in the Detection of Subclinical Chemotherapy-induced Cardiotoxicity in Breast Cancer Patients. International Journal of Medical Imaging, 9(1), 29-35. https://doi.org/10.11648/j.ijmi.20210901.13

Copy | Download

ACS Style

Noura Abdelmonem Atia; Lorenz Lehmann; Mohamed Adel Eltomey; Mohamed Alm El-Din; Johannes Riffel, et al. State-of-the-art CMR Mapping Techniques in the Detection of Subclinical Chemotherapy-induced Cardiotoxicity in Breast Cancer Patients. Int. J. Med. Imaging 2021, 9(1), 29-35. doi: 10.11648/j.ijmi.20210901.13

Copy | Download

AMA Style

Noura Abdelmonem Atia, Lorenz Lehmann, Mohamed Adel Eltomey, Mohamed Alm El-Din, Johannes Riffel, et al. State-of-the-art CMR Mapping Techniques in the Detection of Subclinical Chemotherapy-induced Cardiotoxicity in Breast Cancer Patients. Int J Med Imaging. 2021;9(1):29-35. doi: 10.11648/j.ijmi.20210901.13

Copy | Download

@article{10.11648/j.ijmi.20210901.13,
  author = {Noura Abdelmonem Atia and Lorenz Lehmann and Mohamed Adel Eltomey and Mohamed Alm El-Din and Johannes Riffel and Constantin Dreher and Philipp Bäumer and Anoshirwan Andrej Tavakoli and Norbert Frey and Heinz-Peter Schlemmer and Matthias Friedrich and Mahmoud Abdelaziz Dawoud},
  title = {State-of-the-art CMR Mapping Techniques in the Detection of Subclinical Chemotherapy-induced Cardiotoxicity in Breast Cancer Patients},
  journal = {International Journal of Medical Imaging},
  volume = {9},
  number = {1},
  pages = {29-35},
  doi = {10.11648/j.ijmi.20210901.13},
  url = {https://doi.org/10.11648/j.ijmi.20210901.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijmi.20210901.13},
  abstract = {Background: The oncological treatments have improved survival rates but with an increased risk of cardiovascular disease (CVD). Purpose: To detect subclinical cardiotoxic changes using Cardiovascular Magnetic Resonance (CMR) and to define parameters for the prediction of late cardiac changes after 3 months follow-up. Patients and methods: We conducted a prospective study in 21 breast cancer patients who were scheduled to undergo treatment either with anthracyclines, trastuzumab, or docetaxel. CMR scans were performed before therapy onset as well as 3-6 days and 3 months thereafter. Native left ventricular (LV) T1 and T2 parameters were acquired in addition to standard parameters. Results: Compared to baseline, the mean left ventricular ejection fraction (LVEF) tended to mildly decrease during follow-up. A significant reduction in mean native T1 was found from 1246.6 ± 29.5 ms at baseline to 1231.4 ± 31.4 ms at 3-6 days, which was followed by significant increase after 3 months reaching 1265.8 ± 27.9 ms with p = 0.011 and 0.012, respectively. A significant increase in mean T2 was also found from 41.6 ± 3.4 ms at baseline to 43.8 ± 3.8 ms after 3 months with p = 0.045. From 21 patients, only 1 patient (4.8%) experienced cardiotoxicity. Conclusion: Treatment with potentially cardiotoxic drugs is associated with a change of CMR-derived native T1 which may enable an early identification of cardiotoxicity among breast cancer patients.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - State-of-the-art CMR Mapping Techniques in the Detection of Subclinical Chemotherapy-induced Cardiotoxicity in Breast Cancer Patients
AU  - Noura Abdelmonem Atia
AU  - Lorenz Lehmann
AU  - Mohamed Adel Eltomey
AU  - Mohamed Alm El-Din
AU  - Johannes Riffel
AU  - Constantin Dreher
AU  - Philipp Bäumer
AU  - Anoshirwan Andrej Tavakoli
AU  - Norbert Frey
AU  - Heinz-Peter Schlemmer
AU  - Matthias Friedrich
AU  - Mahmoud Abdelaziz Dawoud
Y1  - 2021/01/15
PY  - 2021
N1  - https://doi.org/10.11648/j.ijmi.20210901.13
DO  - 10.11648/j.ijmi.20210901.13
T2  - International Journal of Medical Imaging
JF  - International Journal of Medical Imaging
JO  - International Journal of Medical Imaging
SP  - 29
EP  - 35
PB  - Science Publishing Group
SN  - 2330-832X
UR  - https://doi.org/10.11648/j.ijmi.20210901.13
AB  - Background: The oncological treatments have improved survival rates but with an increased risk of cardiovascular disease (CVD). Purpose: To detect subclinical cardiotoxic changes using Cardiovascular Magnetic Resonance (CMR) and to define parameters for the prediction of late cardiac changes after 3 months follow-up. Patients and methods: We conducted a prospective study in 21 breast cancer patients who were scheduled to undergo treatment either with anthracyclines, trastuzumab, or docetaxel. CMR scans were performed before therapy onset as well as 3-6 days and 3 months thereafter. Native left ventricular (LV) T1 and T2 parameters were acquired in addition to standard parameters. Results: Compared to baseline, the mean left ventricular ejection fraction (LVEF) tended to mildly decrease during follow-up. A significant reduction in mean native T1 was found from 1246.6 ± 29.5 ms at baseline to 1231.4 ± 31.4 ms at 3-6 days, which was followed by significant increase after 3 months reaching 1265.8 ± 27.9 ms with p = 0.011 and 0.012, respectively. A significant increase in mean T2 was also found from 41.6 ± 3.4 ms at baseline to 43.8 ± 3.8 ms after 3 months with p = 0.045. From 21 patients, only 1 patient (4.8%) experienced cardiotoxicity. Conclusion: Treatment with potentially cardiotoxic drugs is associated with a change of CMR-derived native T1 which may enable an early identification of cardiotoxicity among breast cancer patients.
VL  - 9
IS  - 1
ER  -

Copy | Download